A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

CompletedOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Partial Onset Seizures
Interventions
DRUG

Zonisamide tablets

The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.

Trial Locations (37)

Unknown

Ried

Hillerød

Asperg

Baesweiler

Berlin

Bielefeld

Dortmund

Eisenach

Erbach im Odenwald

Erlangen

Fürth

Gladenbach

Hamburg

Haßfurt

Jülich

Kastellaun

Lage

Lappersdorf

Lauf

Lohr a. Main

Malchin

Mönchengladbach

München

Neuburg an der Donau

Neusaß

Osnabrück

Remscheid

Saarbrücken

Schorndorf

Schwäbisch Gmünd

Senftenberg

Stralsund

Stuttgart

Ulm

Velen

Drammen

Stockholm

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT01830868 - A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM) | Biotech Hunter | Biotech Hunter